Global Lung Cancer Liquid Biopsy Industry Research Report, Growth Trends and Competitive Analysis 2022-2028
Report Code: KNJ1408753 No. of Pages: 105 Category: Pharmaceuticals and Healthcare
Publisher: Date of Publish:
Publisher: Date of Publish:
Report Overview Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Lung Cancer Liquid Biopsy estimated at US$ 492.9 million in the year 2022, is projected to reach a revised size of US$ 1082 million by 2028, growing at a CAGR of 14.0% during the forecast period 2022-2028. The USA market for Lung Cancer Liquid Biopsy is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028. The China market for Lung Cancer Liquid Biopsy is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028. The Europe market for Lung Cancer Liquid Biopsy is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028. The global key companies of Lung Cancer Liquid Biopsy include RainDanceTechnologies, Biocartis, Qiagen, Guardant Health, MDxHealth, Pathway Genomics, NeoGenomics Laboraories, Sysmex Inostics and Cynvenio, etc. In 2021, the global top five players had a share approximately % in terms of revenue. Report Scope This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Lung Cancer Liquid Biopsy companies, distributors, end users, industry associations, governments' industry bureaus, industry publications, industry experts, third party database, and our in-house databases. This report also includes a discussion of the major players across each regional Lung Cancer Liquid Biopsy market. Further, it explains the major drivers and regional dynamics of the global Lung Cancer Liquid Biopsy market and current trends within the industry. Key Companies Covered In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report: RainDanceTechnologies Biocartis Qiagen Guardant Health MDxHealth Pathway Genomics NeoGenomics Laboraories Sysmex Inostics Cynvenio Menarini Silicon Biosystems Adaptive Biotechnologies Biocept Angle plc Market Segments This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028. Lung Cancer Liquid Biopsy Segment by Type Exosomes and RNA CTCs and ctDNA Lung Cancer Liquid Biopsy Segment by Application Hospitals Clinics Others Key Regions & Countries This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028. North America United States Canada Europe Germany France UK Italy Russia Nordic Countries Rest of Europe Asia-Pacific China Japan South Korea Southeast Asia India Australia Rest of Asia Latin America Mexico Brazil Rest of Latin America Middle East & Africa Turkey Saudi Arabia UAE Rest of MEA Key Drivers & Barriers High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects. COVID-19 and Russia-Ukraine War Influence Analysis The readers in the section will understand how the Lung Cancer Liquid Biopsy market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Lung Cancer Liquid Biopsy Market Size Growth Rate by Type: 2017 VS 2021 VS 2028 1.2.2 Exosomes and RNA 1.2.3 CTCs and ctDNA 1.3 Market by Application 1.3.1 Global Lung Cancer Liquid Biopsy Market Growth Rate by Application: 2017 VS 2021 VS 2028 1.3.2 Hospitals 1.3.3 Clinics 1.3.4 Others 1.4 Study Objectives 1.5 Years Considered 2 Market Perspective 2.1 Global Lung Cancer Liquid Biopsy Market Size (2017-2028) 2.2 Lung Cancer Liquid Biopsy Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028 2.3 Global Lung Cancer Liquid Biopsy Market Size by Region (2017-2022) 2.4 Global Lung Cancer Liquid Biopsy Market Size Forecast by Region (2023-2028) 2.5 Global Top Lung Cancer Liquid Biopsy Countries Ranking by Market Size 3 Lung Cancer Liquid Biopsy Competitive by Company 3.1 Global Lung Cancer Liquid Biopsy Revenue by Players 3.1.1 Global Lung Cancer Liquid Biopsy Revenue by Players (2017-2022) 3.1.2 Global Lung Cancer Liquid Biopsy Market Share by Players (2017-2022) 3.2 Global Lung Cancer Liquid Biopsy Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Company Covered: Ranking by Lung Cancer Liquid Biopsy Revenue 3.4 Global Lung Cancer Liquid Biopsy Market Concentration Ratio 3.4.1 Global Lung Cancer Liquid Biopsy Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Lung Cancer Liquid Biopsy Revenue in 2021 3.5 Global Lung Cancer Liquid Biopsy Key Players Head office and Area Served 3.6 Key Players Lung Cancer Liquid Biopsy Product Solution and Service 3.7 Date of Enter into Lung Cancer Liquid Biopsy Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Global Lung Cancer Liquid Biopsy Breakdown Data by Type 4.1 Global Lung Cancer Liquid Biopsy Historic Revenue by Type (2017-2022) 4.2 Global Lung Cancer Liquid Biopsy Forecasted Revenue by Type (2023-2028) 5 Global Lung Cancer Liquid Biopsy Breakdown Data by Application 5.1 Global Lung Cancer Liquid Biopsy Historic Market Size by Application (2017-2022) 5.2 Global Lung Cancer Liquid Biopsy Forecasted Market Size by Application (2023-2028) 6 North America 6.1 North America Lung Cancer Liquid Biopsy Revenue by Company (2020-2022) 6.2 North America Lung Cancer Liquid Biopsy Revenue by Type (2017-2028) 6.3 North America Lung Cancer Liquid Biopsy Revenue by Application (2017-2028) 6.4 North America Lung Cancer Liquid Biopsy Revenue by Country (2017-2028) 6.4.1 U.S. 6.4.2 Canada 7 Europe 7.1 Europe Lung Cancer Liquid Biopsy Revenue by Company (2020-2022) 7.2 Europe Lung Cancer Liquid Biopsy Revenue by Type (2017-2028) 7.3 Europe Lung Cancer Liquid Biopsy Revenue by Application (2017-2028) 7.4 Europe Lung Cancer Liquid Biopsy Revenue by Country (2017-2028) 7.4.1 Germany 7.4.2 France 7.4.3 U.K. 7.4.4 Italy 7.4.5 Russia 8 Asia Pacific 8.1 Asia Pacific Lung Cancer Liquid Biopsy Revenue by Company (2020-2022) 8.2 Asia Pacific Lung Cancer Liquid Biopsy Revenue by Type (2017-2028) 8.3 Asia Pacific Lung Cancer Liquid Biopsy Revenue by Application (2017-2028) 8.4 Asia Pacific Lung Cancer Liquid Biopsy Revenue by Region (2017-2028) 8.4.1 China 8.4.2 Japan 8.4.3 South Korea 8.4.4 India 8.4.5 Australia 8.4.6 China Taiwan 8.4.7 Indonesia 8.4.8 Thailand 8.4.9 Malaysia 9 Latin America 9.1 Latin America Lung Cancer Liquid Biopsy Revenue by Company (2020-2022) 9.2 Latin America Lung Cancer Liquid Biopsy Revenue by Type (2017-2028) 9.3 Latin America Lung Cancer Liquid Biopsy Revenue by Application (2017-2028) 9.4 Latin America Lung Cancer Liquid Biopsy Revenue by Country (2017-2028) 9.4.1 Mexico 9.4.2 Brazil 9.4.3 Argentina 10 Middle East and Africa 10.1 Middle East and Africa Lung Cancer Liquid Biopsy Revenue by Company (2020-2022) 10.2 Middle East and Africa Lung Cancer Liquid Biopsy Revenue by Type (2017-2028) 10.3 Middle East and Africa Lung Cancer Liquid Biopsy Revenue by Application (2017-2028) 10.4 Middle East and Africa Lung Cancer Liquid Biopsy Revenue by Country (2017-2028) 10.4.1 Turkey 10.4.2 Saudi Arabia 10.4.3 UAE 11 Company Profiles 11.1 RainDanceTechnologies 11.1.1 RainDanceTechnologies Company Details 11.1.2 RainDanceTechnologies Business Overview 11.1.3 RainDanceTechnologies Lung Cancer Liquid Biopsy Products and Services 11.1.4 RainDanceTechnologies Lung Cancer Liquid Biopsy Revenue in Lung Cancer Liquid Biopsy Business (2017-2022) 11.1.5 RainDanceTechnologies Lung Cancer Liquid Biopsy SWOT Analysis 11.1.6 RainDanceTechnologies Recent Developments 11.2 Biocartis 11.2.1 Biocartis Company Details 11.2.2 Biocartis Business Overview 11.2.3 Biocartis Lung Cancer Liquid Biopsy Products and Services 11.2.4 Biocartis Lung Cancer Liquid Biopsy Revenue in Lung Cancer Liquid Biopsy Business (2017-2022) 11.2.5 Biocartis Lung Cancer Liquid Biopsy SWOT Analysis 11.2.6 Biocartis Recent Developments 11.3 Qiagen 11.3.1 Qiagen Company Details 11.3.2 Qiagen Business Overview 11.3.3 Qiagen Lung Cancer Liquid Biopsy Products and Services 11.3.4 Qiagen Lung Cancer Liquid Biopsy Revenue in Lung Cancer Liquid Biopsy Business (2017-2022) 11.3.5 Qiagen Lung Cancer Liquid Biopsy SWOT Analysis 11.3.6 Qiagen Recent Developments 11.4 Guardant Health 11.4.1 Guardant Health Company Details 11.4.2 Guardant Health Business Overview 11.4.3 Guardant Health Lung Cancer Liquid Biopsy Products and Services 11.4.4 Guardant Health Lung Cancer Liquid Biopsy Revenue in Lung Cancer Liquid Biopsy Business (2017-2022) 11.4.5 Guardant Health Lung Cancer Liquid Biopsy SWOT Analysis 11.4.6 Guardant Health Recent Developments 11.5 MDxHealth 11.5.1 MDxHealth Company Details 11.5.2 MDxHealth Business Overview 11.5.3 MDxHealth Lung Cancer Liquid Biopsy Products and Services 11.5.4 MDxHealth Lung Cancer Liquid Biopsy Revenue in Lung Cancer Liquid Biopsy Business (2017-2022) 11.5.5 MDxHealth Lung Cancer Liquid Biopsy SWOT Analysis 11.5.6 MDxHealth Recent Developments 11.6 Pathway Genomics 11.6.1 Pathway Genomics Company Details 11.6.2 Pathway Genomics Business Overview 11.6.3 Pathway Genomics Lung Cancer Liquid Biopsy Products and Services 11.6.4 Pathway Genomics Lung Cancer Liquid Biopsy Revenue in Lung Cancer Liquid Biopsy Business (2017-2022) 11.6.5 Pathway Genomics Lung Cancer Liquid Biopsy SWOT Analysis 11.6.6 Pathway Genomics Recent Developments 11.7 NeoGenomics Laboraories 11.7.1 NeoGenomics Laboraories Company Details 11.7.2 NeoGenomics Laboraories Business Overview 11.7.3 NeoGenomics Laboraories Lung Cancer Liquid Biopsy Products and Services 11.7.4 NeoGenomics Laboraories Lung Cancer Liquid Biopsy Revenue in Lung Cancer Liquid Biopsy Business (2017-2022) 11.7.5 NeoGenomics Laboraories Lung Cancer Liquid Biopsy SWOT Analysis 11.7.6 NeoGenomics Laboraories Recent Developments 11.8 Sysmex Inostics 11.8.1 Sysmex Inostics Company Details 11.8.2 Sysmex Inostics Business Overview 11.8.3 Sysmex Inostics Lung Cancer Liquid Biopsy Products and Services 11.8.4 Sysmex Inostics Lung Cancer Liquid Biopsy Revenue in Lung Cancer Liquid Biopsy Business (2017-2022) 11.8.5 Sysmex Inostics Lung Cancer Liquid Biopsy SWOT Analysis 11.8.6 Sysmex Inostics Recent Developments 11.9 Cynvenio 11.9.1 Cynvenio Company Details 11.9.2 Cynvenio Business Overview 11.9.3 Cynvenio Lung Cancer Liquid Biopsy Products and Services 11.9.4 Cynvenio Lung Cancer Liquid Biopsy Revenue in Lung Cancer Liquid Biopsy Business (2017-2022) 11.9.5 Cynvenio Lung Cancer Liquid Biopsy SWOT Analysis 11.9.6 Cynvenio Recent Developments 11.10 Menarini Silicon Biosystems 11.10.1 Menarini Silicon Biosystems Company Details 11.10.2 Menarini Silicon Biosystems Business Overview 11.10.3 Menarini Silicon Biosystems Lung Cancer Liquid Biopsy Products and Services 11.10.4 Menarini Silicon Biosystems Lung Cancer Liquid Biopsy Revenue in Lung Cancer Liquid Biopsy Business (2017-2022) 11.10.5 Menarini Silicon Biosystems Lung Cancer Liquid Biopsy SWOT Analysis 11.10.6 Menarini Silicon Biosystems Recent Developments 11.11 Adaptive Biotechnologies 11.11.1 Adaptive Biotechnologies Company Details 11.11.2 Adaptive Biotechnologies Business Overview 11.11.3 Adaptive Biotechnologies Lung Cancer Liquid Biopsy Products and Services 11.11.4 Adaptive Biotechnologies Lung Cancer Liquid Biopsy Revenue in Lung Cancer Liquid Biopsy Business (2017-2022) 11.11.5 Adaptive Biotechnologies Recent Developments 11.12 Biocept 11.12.1 Biocept Company Details 11.12.2 Biocept Business Overview 11.12.3 Biocept Lung Cancer Liquid Biopsy Products and Services 11.12.4 Biocept Lung Cancer Liquid Biopsy Revenue in Lung Cancer Liquid Biopsy Business (2017-2022) 11.12.5 Biocept Recent Developments 11.13 Angle plc 11.13.1 Angle plc Company Details 11.13.2 Angle plc Business Overview 11.13.3 Angle plc Lung Cancer Liquid Biopsy Products and Services 11.13.4 Angle plc Lung Cancer Liquid Biopsy Revenue in Lung Cancer Liquid Biopsy Business (2017-2022) 11.13.5 Angle plc Recent Developments 12 Lung Cancer Liquid Biopsy Market Dynamics 12.1 Lung Cancer Liquid Biopsy Market Trends 12.2 Lung Cancer Liquid Biopsy Market Drivers 12.3 Lung Cancer Liquid Biopsy Market Challenges 12.4 Lung Cancer Liquid Biopsy Market Restraints 13 Research Findings and Conclusion 14 Appendix 14.1 Research Methodology 14.1.1 Methodology/Research Approach 14.1.2 Data Source 14.2 Author Details
NEED Help?
If you need any help or guidance, please feel free to call us.
USA : +1 (661) 636 6162
INDIA : +91 9325802062
or
Write us on : sales@kandjmarketresearch.com